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Background: The up-regulation of pro-inflammatory agents, amongst them tumor necrosis 
factor (TNF), may represent low-grade inflammation in major depression. To further 
elucidate inflammatory mechanisms related to TNF in depression, the aim of the current study 
was to investigate the involvement of ligands and receptors of the TNF/TNF-receptor-
superfamily yet un- or little explored in major depression.  
Methods: Serum levels of ligands (TNF, TNF-related weak inducer of apoptosis [TWEAK], 
B-cell activating factor [BAFF], tumor necrosis factor superfamily member 14 [TNFSF14; 
LIGHT], A proliferation-inducing ligand [APRIL]) and receptor molecules (TNF receptor 
superfamily member 8 [TNFRSF8; sCD30], soluble TNF receptor type 1 [sTNFR1] and type 
2 [sTNFR2]) of the TNF/TNF-receptor-superfamily were measured in 50 unmedicated 
patients suffering from major depression and 48 healthy controls and were reassessed in 37 of 
the depressed patients two weeks after the initiation of antidepressive treatment.  
Results: In comparison to the healthy controls, the interrelated serum levels of TWEAK, 
BAFF, TNFSF8, sTNFR1 and sTNFR2 were reduced both in the unmedicated and medicated 
depressed patients. Serum levels of BAFF and TNF significantly increased during the 
initiation of antidepressive treatment. In the combined sample of unmedicated depressed and 
healthy controls, but not the separate groups, scores of the BDI-II inversely correlated with 
levels of TWEAK, BAFF, sTNFR1, sTNFR2 and TNFSF8.  
Conclusion: The current findings give evidence for a role of the TNF/TNF-receptor-
superfamily in the pathophysiology of major depression that may involve reduced tissue 
regeneration and neurogenesis rather than an acceleration of pro-inflammatory pathways.  
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1. Introduction  
A low-grade inflammation with an up-regulation of inflammatory cytokines is believed to be 
related to the etiopathogenesis of major depression, potentially its course and treatment 
outcome (Leonard, 2018; Bufalino et al., 2013; Köhler et al., 2018; Schmidt et al., 2014; 
Schmidt et al., 2016). As a central component of the innate immune system and as one the 
most frequent cytokines investigated in major depression (Köhler et al., 2017), tumor necrosis 
factor (TNF; tumor necrosis factor ligand superfamily member 2 [TNFSF2]) may be involved 
in major depression not just by activating certain cascades of inflammation but by a series of 
mechanisms: TNF induces the indolamine-2,3-dioxygenase (IDO), which mediates the shift 
of metabolism of tryptophan away from 5-hydroxytryptamine (5-HT) to kynurenine, and the 
increased transformation of kynurenine to neurotoxic quinolinic acid (Leonard, 2018; 
Lichtblau et al., 2013); TNF mediates the depletion of the active fraction of 5-HT by 
activating serotonin transporter (Malynn et al., 2013), disrupts the negative feedback loop of 
the hypothalamic-pituitary-adrenal- (HPA) -axis by stimulating the excessive release of 
corticotrophin-releasing hormone (CRH) (Zunszain, 2011), contributes to increased redox 
signaling of nitric oxide (NO) (Moylan et al., 2014) but at the same time, is involved in 
hippocampal neurogenesis (McCoy and Tansey, 2008). 
TNF is eponymous for the TNF/TNF-receptor-superfamily (TNF/TNFRSF), which consists of 
ligands with functional and structural similarities to TNF and receptors that contribute to 
inflammation, cell growth, survival or death (Croft et al., 2013). Except for few studies 
showing increased levels of the soluble forms of the TNF-receptors (sTNFR1 and sTNFR2) 
(Grassi-Oliveira et al., 2009; Papakostas et al., 2013; Diniz et al., 2010), data on components 
of the TNF/TNF-receptor-superfamily, such as the ligands TNFSF12 (= TNF-related weak 
inducer of apoptosis [TWEAK]), TNFSF13 (= A proliferation-inducing ligand [APRIL]), 
TNFSF13B (= B-cell activating factor [BAFF] and TNFSF14 [LIGHT], or the TNF-receptor 
TNFRSF8 [= sCD30], are scarce or lacking in major depression.  
Given the paucity in studies reporting on parameters of the TNF/TNFRSF other than TNF and 
the central involvement of TNF family members in inflammatory, apoptotic as well as 
neuroprotective processes related to major depression, the aim of the current study was to 
exploratory compare serum levels of hitherto un- and little explored components of the 
TNF/TNFRSF between subjects with major depression and non-depressed controls and, 
hence, to give further evidence for a disruption of the immune system in major depression.  
 
2. Methods 
2.1. Subjects and overall design 
The sample of 50 antidepressant-free depressed patients consisted of depressed in- and 
outpatients consecutively recruited between 02/2012 and 12/2016 from the Department of 
Psychiatry and Psychotherapy of the University Hospital Leipzig as part of the VIRAP 
(‘Vigilance Regulation as Response Predictor in Antidepressant Therapy; Schmidt et al., 
2017) project. Measurements were repeated in 37 patients 14 ± 1 days following the onset of 
antidepressant treatment (T2). At both points of measurement a German version of a 
structured interview (Wiliams et al., 1988) was performed to assess the Hamilton Depression 
Rating Scale (HAMD-17; Hamilton, 1960) and the Inventory of Depressive Symptomatology 
(IDS; Rush et al., 1996). Antidepressant therapy within two weeks of assessment consisted of 
a monotherapy with either escitalopram or mirtazapine. Data sets of 48 non-depressed 
controls were selected from a pool of participants recruited as part of the ‘OBDEP’ research 
project (Obesity and Depression: pathogenetic role of sleep and wakefulness regulation, 
motor activity level and neurochemical aspects; Schmidt et al., 2014). For this project, 304 
participants were initially recruited from the outpatient clinic of the Integrated Research and 
Treatment Centre for Adiposity Diseases Leipzig (IFB), from the Department of Psychiatry 
and Psychotherapy of the University Hospital Leipzig and via advertisements (intranet, 
internet, local newspapers). The assessment of the non-depressed controls was performed in 
two steps: After completing a telephone screening interview, which involved collecting socio-
demographic data, assessing the presence of somatic disorders and completing a checklist of 
the Structured Clinical Interview for DSM-IV (SCID-I) (Wittchen et al., 1997), potentially 
eligible participants were invited to the study center to assess in- and exclusion criteria in 
more detail. In both, depressed participants and healthy controls, a Beck Depression Inventory 
was obtained (BDI-II; Beck et al., 1996). A Structured Clinical Interview (SCID-I) was 
performed to support the assessment of inclusion and exclusion criteria. The diagnosis of 
major depression with a current episode of depression represented an inclusion criterion for 
the depressed patients and an exclusion criterion for the non-depressed controls. An inclusion 
criterion for both groups was age ≥ 18 years. For both groups, exclusion criteria were: use of 
centrally active medications (including antidepressants) and non-steroidal anti-inflammatory 
drugs (NSAID) during the previous two weeks; serious suicide risk; organic mental disorders; 
use of illegal drugs and/or alcohol abuse within the past 6 months; schizophrenia, schizotypal 
and delusional disorders; a history of head injury with loss of consciousness exceeding 1 hour 
and epilepsy. For the depressed and non-depressed participants, assessments of current and 
past history of physical and mental health problems as well as current medication were 
performed using standardized forms. Patients suffering from conditions of current 
inflammation, inflammatory diseases and autoimmune disorders were excluded from 
participation. Drugs and disorders potentially affecting cytokine levels are listed in table 1.   
Written informed consent was obtained from all participants. The study was performed 




2.2. Cytokine measurements 
After blood drawing, serum probes were immediately centrifuged at 3000 rpm for 10 minutes. 
The supernatant was aliquoted and stored in non-absorbing polypropylene tubes of 300 μl. 
Probes were snap-frozen in liquid nitrogen and stored at -80 ºC until further measurements 
were conducted. TNF was measured using the Bio-Plex Pro Human Chemokine TNF-α Set, 
Bio Rad, Germany. All other parameters were measured with the Bio-Plex Pro Human 
Inflammation Assay, Bio Rad, Germany, 96-well kits that include coupled magnetic beads 
and detection antibodies. All analyses were performed at the Institute of Laboratory Medicine, 
University Hospital Ludwig-Maximilian-University Munich, Germany. The intraassay 
coefficient of variance (CV) of the parameters of the Inflammation Assay included into the 
statistical analyses was between 8.53 and 17.62 % for plate one and 1.78 and 4.66 % for plate 
two, the intra-assay CV for TNF was between 1.54 and 1.6. The interassay CV was between 
0.15 and 6.44 %. For LIGHT, all except 10 analytes (7.4 % of the total samples) were below 
the lower limit of quantification (LLOQ) of 3.1 pg/ml. None of the other probes were below 
or above the lower (LLOQ) and upper (ULOQ) limit of quantification.   
 
2.3. Statistics 
Following the four-fold dilution of the samples volumes during the preparation process 
preceding the measures, all levels of all mediators were multiplied by the factor 4 before 
statistical analyses were conducted. Extreme outliers for each of the parameters in the total of 
the 135 probes were excluded for the respective analyses, identified when meeting 
‘value>3*interquartile range’. Following Gaussian (TWEAK, BAFF, sTNFR1, sTNFR2) and 
non-Gaussian distribution (APRIL, TNFRSF8, TNF) of log-transformed values, either 
multivariate analysis of variance (MANOVA) or generalized linear models (GLM) were 
performed for the analyses between groups. The following variables were included into the 
analyses as covariates when significantly correlating with TNF/TNF-receptor-superfamily 
members and/or when they differed between the depressed and non-depressed participants: 
BMI, sex, smoking status, number of somatic disorders and medication. Paired t-tests or 
Wilcoxon signed-rank tests were performed to analyze changes in cytokine levels between the 
assessment points. The correlation coefficients between the parameters and severities of 
depression were assessed via Spearman rank correlations. The level of significance was set at 
p <0.05 for all analyses. All analyses were performed with SPSS Version 24. 
 
3. Results   
3.1. Socio-demography  
The 50 depressed patients and the 48 healthy controls did not differ in age and sex 
distribution, whereas more depressed patients were current smokers and the healthy controls 
showed a higher BMI. Both groups did not differ in the presence of somatic disorders and 
drugs that could potentially influence cytokine levels. Depression severities and 
characteristics of depression are listed in table 1.  
 
3.2. Comparisons of levels of TNF/TNF-receptor-superfamily members between 
groups  
Analyses between the group of unmedicated depressed subjects and the healthy subjects 
revealed significantly lower levels of BAFF, TWEAK, TNFRSF8, sTNFR1 and sTNFR2 in 
the group of depressed subjects (Table 2; Figure 1). Levels of APRIL and TNF-α did not vary 
significantly between the two groups. Levels of LIGHT could only be detected in 8 healthy 
controls (37.28 pg/ml ± 26.03 pg/ml SD), whereas all levels within the depressed patients 
were below the detection range.  
Comparisons between the medicated depressed patients at T2 and the healthy controls 
revealed significantly lower levels of BAFF, TWEAK, sTNFR1 and sTNFR2 within the 
depressed subjects. The two groups did not differ significantly in levels of APRIL, TNFRSF8 
and TNF.  
 
3.3. TNF/TNF-receptor-superfamily members and the clinical course, response and 
medication 
From baseline to T2, serum levels of BAFF and TNF increased significantly within the total 
group of depressed patients, whereas levels of APRIL, TWEAK, TNFRSF8, sTNFR1 and 
sTNFR2 did not vary between the two points of time (Table 2; Figure 1).  
Comparisons in cytokine levels between responders (response defined as a 40 % decrease in 
HAMD-17 sum score from baseline to T2; N = 14) and non-responders (N = 23) revealed 
significantly higher baseline levels of TWEAK in the responders (476.52 pg/ml ± 119.06 
pg/ml) versus the non-responders (388.94 pg/ml ± 84.83 pg/ml; p = 0.008). Changes in levels 
from baseline to T2 significantly varied for TWEAK only (F = 4.815, p = 0.035), showing a 
slight decrease in the responders (T2: 423.10 pg/ml ± 202.78 pg/ml) and an increase in the 
non-responders (T2: 408.63 pg/ml ± 106.81 pg/ml). 
Comparisons between patients receiving escitalopram (N = 25) and mirtazapine (N= 12) did 
not reveal significant differences for any of the parameters at baseline or T2. For changes 
from baseline to T2, no significant time*medication interaction could be observed. 
 
3.4. Associations between levels of TNF/TNF-receptor-superfamily members and 
clinical variables  
In the total study sample but not the separate groups, BDI-II sum scores inversely correlated 
with levels of BAFF (R = -0.339, p < 0.001), TWEAK (R = -0.334, p = 0.001), sTNFR1 (R = 
-0.388, p < 0.001) and sTNFR2 (R = -0.467, p < 0.001). Scores of HAMD-17 and IDS-C did 
not significantly correlate with the parameters in the unmedicated and medicated depressed 
patients. sTNFR1, but none of the other parameters, was higher in melancholic (N= 28; 2.61 
ng/ml ± 0.66 ng/ml SD) versus non-melancholic depressed patients (2.20 ng/ml ± 0.64 ng/ml 
SD; p = 0.023). Concerning the number of episodes, solely TNFRSF8 was significantly 
elevated in the patients with the first compared to patients with recurrent depressive episodes 
(338.04 pg/ml ± 159.28 pg/ml SD; recurrent: 251.63 pg/ml ± 101.60 pg/ml SD; p = 0.048) 
and weakly correlated with the number of depressive episodes (R = -0.285, p = 0.045).  
 
3.5. Associations between levels of TNF/TNF-receptor-superfamily members and 
socio-demography  
In the total sample, the BMI correlated significantly with BAFF (r = 0.310, p = 0.002), 
sTNFR1 (r = 0.370, p < 0.001), sTNFR2 (r = 0.545, p < 0.001) and TNFRSF8 (R = 0.219, p = 
0.035), but not with TWEAK, APRIL or TNF. Age correlated with APRIL (R = 0.536, p < 
0.001) but none of the other mediators. APRIL, but not the other mediators, was found to be 
higher in the total of male participants (30.18 ng/ml ± 18.92 ng/ml SD) compared to female 
participants (19.54 ng/ml ± 12.79 ng/ml SD; p = 0.002) and in the healthy males (34.59 ng/ml 




In this exploratory, prospective study, differences in the levels of eight different ligands and 
receptors of the TNF/TNF-receptor-superfamily were investigated and compared between 
depressed and non-depressed subjects. Extending findings on TNF, to the best of the authors’ 
knowledge, this is the first investigation on the ligands BAFF, TWEAK, APRIL and LIGHT 
in major depression, and adds to the few studies on TNF-receptors TNFRSF8, sTNFR1 and 
sTNFR2 (Grassi-Oliveira et al., 2009; Papakostas et al., 2013; Diniz et al., 2010; Merendino 
et al., 2002). As the major results, group comparisons revealed significantly reduced means 
for BAFF, TWEAK, TNFRSF8, sTNFR1 and sTNFR2 in the unmedicated patients compared 
to non-depressed subjects, which did not normalize within the first phase of antidepressant 
treatment.  
Seemingly, the reductions in mean levels contrast the assumption of a persistent, low grade 
inflammation to occur in major depression for which the TNF-system is of central 
importance. For instance, TNF has been shown to impair the monoamine neurotransmitter 
synthesis, which leads to a reduced availability for the synthesis of serotonin (Malynn et al., 
2013) and an increased accumulation of neuro-toxic metabolites (Lichtblau et al., 2013). 
Further, TNF increase the expression and function of monoamine reuptake pumps and results 
in a reduced synthesis of different neurotrophic growth factors (Leonard, 2018; ). 
Consecutively, levels of TNF and the TNF-receptors TNFRSF8, sTNFR1 and sTNFR2 were 
previously found increased (Köhler et al., 2017; Grassi-Oliveira et al., 2009; Papakostas et al., 
2013; Diniz et al., 2010; Merendino et al., 2002). However, we could observe an overlap in 
levels between the depressed and healthy persons for nearly every TNF-member, especially 
reductions in the cytokine levels in a considerable proportion of patients. In line with this, the 
power of cytokines to discriminate between depression and health is yet low due to the 
substantial overlap in levels between acutely depressed, remitters and healthy subjects. 
Secondly, cytokine alterations are considered as unspecific due to the varying influence of 
social, psychological, biological, and medical factors (Himmerich et al., 2019). In contrast, 
other investigations come to the conclusion that cytokine alterations either represent a specific 
subtype of depression (Lotrich, 2015), that they particularly occur in sub-groups of depressed 
subjects, such as atypical depression (Woelfer et al., 2019), or that they are related to some 
clinical features of the disorder (Schmidt et al., 2018; Euteneuer et al., 2017). Our findings 
that only few TNF-family members showed a relationship with the type of depression, the 
history of the disorder or the severity do not portend the aforementioned three assumptions. 
Nonetheless, given that a relevant proportion of the depressed subjects in this study exhibited 
reduced levels of the TNF-family members which are also involved in anti-inflammation 
regulation, tissue regeneration and neurogenesis, our present results challenge the assumption 
of a one-sided increase in cytokine levels in depression. Some features of the cytokines would 
indicate that also reductions in concentrations could participate in the pathogenesis of 
depression.  
As such, BAFF is an important homeostatic signal for the B cell survival and selection, whose 
expression depends upon the B cell activity (Moisini and Davidson, 2009; Kreuzaler et al., 
2012). One may speculate that the increase in B cells observed in depressed patients (Maes et 
al., 1992), accompanied with the up-regulation of BAFF receptors, leads to auto-regulatory 
reductions in concentrations of BAFF in major depression. On the opposite, the reduction of 
naïve B cells in major depression (Ahmetspahic et al., 2017) may be a consequence following 
the reductions in BAFF-concentrations and the missing anti-apoptotic features of BAFF.  
TNFRSF8, for which the soluble sCD30 represents the extracellular fraction, is expressed by 
both active T and B cells and involved in proliferative and anti-apoptotic pathways as well as 
the control of both CD4+ T cell effector function and CD4+ T cell memory (Withers et al., 
2011; van der Weyden et al., 2017). Some evidence supports our finding of a reduction of 
TNFRSF8 in subjects suffering from major depression: TNFRSF8 enhances resistance to the 
apoptosis of CD4+ T cells (Hirsch et al., 2010), whereas depressed patients exhibit signs of 
accelerated apoptosis of CD4+ T cells (Szuster-Ciesielska et al., 2008). In parallel to a shift in 
the Th2/Th1 balance towards Th1 in major depression (Komori, 2017), TNFRSF8 was found 
reduced in patients with T-helper cell type 1 (Th1)-associated disorders and increased in 
patients with Th2-associated diseases (D’Elios et al., 1997; van der Weyden et al., 2017). 
Reports to compare our results with are scarce: the yet solitary investigation on TNFRSF8 in 
major depression reported unchanged concentrations in comparison to non-depressed subjects 
– however interpretations of these results are limited since only ten depressed patients had 
been included and the status of medication could have influenced the concentrations 
(Merendino et al., 2002).  
For TWEAK, which modulates inflammation, cell proliferation and apoptosis (Winkles, 
2008), no data on major depression yet exists. As an argument for a reduction of TWEAK to 
facilitate a pro-inflammatory state in major depression, TWEAK was found to attenuate the 
transition to adaptive Th1 immunity (Maecker et al. 2005) and to inhibit TNF-R1 signalling 
(Wicovsky et al., 2009). Consequently, the depletion in TWEAK may, again, lead to higher 
Th1 activation and reduced suppression of pro-inflammatory cytokine production (Maecker et 
al. 2005). 
The reductions of TNF-effecting receptors sTNFR1 and sTNFR2 (McCoy and Tansey, 2008; 
Faustman and Davis, 2013) in the majority of the depressed patients contrast previous studies 
reporting on elevated levels of sTNFR2 (Papakostas et al., 2013; Diniz et al., 2010) and both 
sTNFR1 and sTNFR2 (Grassi-Oliveira et al., 2009; Brunoni et al., 2015). TNFR2 is critically 
involved in outbalancing the activity of regulatory T cells (Tregs) and T effector cells (Teffs; 
Ye et al., 2018; Chen and Oppenheim, 2018), and a down-regulation of TNFR2 may 
potentially skew T cell differentiation observed in major depression (Patas et al., 2018). 
Further, we may speculate that affections in concentrations of TNFR2 and TNFR1 relates to 
structural and functional alterations in major depression since levels of TNFR2 were found 
reduced in the dorsolateral prefrontal cortex (DLPFC) in post mortem brain tissue of patients 
with a major depression (Dean et al., 2013). Lower TNFR2 levels were also associated with 
lower activity in the ACC (Slavich et al., 2010), whose activity was found reduced in major 
depression (Saletu et al., 2010). Further indicative for reductions in TNFR2 at least in a parts 
of subjects suffering from major depression in which hippocampal function is impaired 
(Schmaal et al., 2016; Dietsche et al., 2014), TNF was found to have trophic effects in the 
hippocampus when TNFR2 was overexpressed (Yang et al., 2002), whereas TNF alone 
inhibits neurite outgrowth and branching (Neumann et al., 2002).  
Concerning the dynamics of cytokines within the first two weeks of treatment, BAFF and 
TNF were found to increase. Although we could not identify a specific association with the 
drugs administered, there is good evidence that at least mirtazapine has pro-inflammatory 
properties, at it has previously been found to increase TNF-levels (Petersein et al., 2015). 
Following the long-term treatment, dynamics of peripheral TNF-levels were found to vary 
widely with a tendency towards a decrease (Köhler et al., 2017). As the changes in the 
majority of cytokines were not related to the clinical response here and previously (Köhler et 
al., 2017; Schmidt et al., 2016), the potential of cytokines as a clinically useful prediction 
marker seems to be small. However, as both baseline and changes in levels of TWEAK were 
found associated with the early response, this may be a parameter worth looking into when 
examining the association between members of the TNF-system and the clinical course.  
Limitations of our study include that, although the BMI and the smoking habits were included 
as covariates into statistical analyses, an influence of the differences caused by these variables 
between the groups cannot entirely be ruled out. A relationship between depression severities 
and the majority of the parameters could be observed in the total sample but not the separate 
groups which could indicate a type-II-error. The results in the sub-group analyses have to be 
interpreted with caution, given the small sample sizes. No re-assessment of the parameters 
was performed in the healthy controls which could have helped interpreting the dynamics 
within the depressed patients. Other parameters which could underpin the arguments of 
reduced neuroprotective and regenerative properties of some of the investigated parameters 
within major depression, such as as PI3K/Akt, GSK3 or CREB, are lacking. Finally, potential 
mechanisms underlying the alterations in serum cytokine levels are outlined in the discussion, 
however, our study did not include experiments unraveling these possible mechanisms.  
In conclusion, our findings of reduced serum levels of TNF/TNF-receptor-superfamily 
members in antidepressant-free and medicated depressed patients compared to non-depressed 
controls provide further insights into the role of inflammatory agents in major depression. 
Variation in levels may arise from changes in inflammatory cascades observed in major 
depression, such as a shift in the Th2/Th1 balance, an increased apoptosis of CD4+ T cells or 
alterations in the overall B-cells or a reduced blockade of TNF. The results may encourage 
further studies to provide insights into the mechanisms of the mediator actions specifically in 
major depression, as well as studies dealing with the interactions between antidepressants and 
the mediators of the TNF/TNF-receptor-superfamily. 
 
5. Tables 
Table 1: Socio-demography and clinical variables 
Annotations: A = t-test, B = Chi2-test, C = Mann-Whitney-U-test 
 
Table 2: Serum levels of TNF/TNF-receptor-superfamily members between depressed 
and non-depressed subjects 
 
Annotations: A = MANOVA with ‘age’, ‘smoking’, and ‘BMI’ as covariates, B = generalized linear model 
(GLM) with ‘age’, ‘sex’, ‘smoking’ and ‘BMI’ as covariates, C = GLM with ‘smoking’ and ‘BMI’ as covariates, 
D = paired t-test, E = Wilcoxon test. 
 
6. Figure 
Figure 1: Serum levels of TNF/TNF-receptor-superfamily members between depressed 
and non-depressed subjects 
Annotations: *p < 0.05, **p < 0.01, *** p< 0.001, HC=healthy controls, 
MDD_T1=unmedicated depressed subjects, MDD_T2=medicated depressed subjects 
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